AAV-mediated Tet2 modulation in 2×Tg-AD mice behavioral study

Validation Score: 0.900 Price: $0.50 Alzheimer's disease young APPswe/PSEN1 double-transgenic mice Status: proposed

What This Experiment Tests

Validation experiment designed to validate causal mechanisms targeting TET2 in young APPswe/PSEN1 double-transgenic mice. Primary outcome: cognitive performance and amyloid burden

Description

This in vivo experiment investigated the functional role of Tet2 in cognition and amyloid pathology using adeno-associated virus (AAV)-mediated gene delivery in 2×Tg-AD mice. Recombinant AAV vectors were stereotaxically microinjected into the bilateral dentate gyrus regions of the hippocampus to achieve either Tet2 knockdown or overexpression. The study examined young 2×Tg-AD mice to determine how manipulating Tet2 levels affected cognitive function and amyloid load. The researchers found that knocking down Tet2 in young 2×Tg-AD mice resulted in cognitive impairments, while the effects of Tet2 overexpression on cognition and amyloid pathology were also evaluated.

TARGET GENE

TET2 (Score: 0.584)

MODEL SYSTEM

young APPswe/PSEN1 double-transgenic mice

ESTIMATED COST

TIMELINE

0 months

PATHWAY

epigenetic regulation/memory formation

SOURCE

extracted_from_pmid_33165916

PRIMARY OUTCOME

cognitive performance and amyloid burden

Scoring Dimensions

📖 Wiki Pages

TET2 Genegene aav-gene-therapy-neurodegenerationtherapeutic AAV Serotype Comparison for LRRK2 Knockdown in PD experiment AAV Capsid Engineering for CNS-Targeted Neurodegenidea AAV Gene Therapy Vectors for Neurodegenerationmechanism AAV Gene Therapy Vectors for Neurodegenerative Distherapeutic AAV Serotype Comparison for LRRK2 Knockdown in PDexperiment AAV-LRRK2 IND-Enabling Study Designexperiment AAV-LRRK2 Gene Therapy IND-Enabling Study Designexperiment AAV-Delivered RNA Targeting Therapy for Neurodegenidea AAV Serotype CNS Delivery Optimization Therapytherapy AAV Gene Therapy for Neurodegeneration — Investmeninvestment AAV-LRRK2 Gene Delivery Modelmodel AAV Vectors for Neurodegenerative Disease Gene Thetechnology AAV Gene Therapy for Neurodevelopmental Epilepsy —therapeutic

Protocol

Establish young APPswe/PSEN1 double-transgenic mice cohorts for Alzheimer's disease and predefine inclusion, exclusion, and quality-control criteria before intervention. 2. Apply the experimental manipulation described for TET2, alongside matched control or comparator arms, and document dose, exposure window, and sample timing in a locked protocol log. 3. Measure cognitive performance and amyloid burden together with orthogonal secondary readouts such as molecular, imaging, behavioral, or safety endpoints that are appropriate to the title and study design. 4. Use blinded outcome assessment where feasible, prespecified statistical analysis, and replicate the core readout across biological replicates or an independent validation subset. 5.

...

Expected Outcomes

The intervention targeting TET2 shifts cognitive performance and amyloid burden in the predicted direction relative to the matched control arm.

Secondary disease-relevant readouts in Alzheimer's disease remain directionally concordant with the primary endpoint rather than showing isolated single-assay effects.

The effect persists after adjustment for baseline covariates, batch effects, or repeated-measures structure used in the study design.

Success Criteria

Prespecified primary endpoint (cognitive performance and amyloid burden) improves versus control with p < 0.05 or an equivalent corrected threshold used by the study.
The effect size is biologically meaningful and reproduced across technical/biological replicates or the validation subset.
Safety, data quality, and missingness remain within protocol-defined bounds so the result is interpretable rather than driven by attrition or assay failure.

Related Hypotheses (5)

Cell-Type Specific TREM2 Upregulation in DAM Microglia0.761

Epigenetic Memory Erasure via TET2 Activation0.741

TET2-Mediated Demethylation Rejuvenation Therapy0.706

Temporal TET2-Mediated Hydroxymethylation Cycling0.657

LRP1-Dependent Tau Uptake Disruption0.600

Debate History (0)

No debates yet

Experiment Results (0)

No results recorded yet. Use POST /api/experiments/{id}/results to record a result.